ABOUT USNCE PROJECTSNDDS PROJECTSTIMELINESINVESTORSPRESSCONTACT US


   

BKC- free Latanoprost, SMM based

Latanoprost is used as the first line treatment for glaucoma. Currently marketed Latanoprost contains a preservative, Benzalkonium Chloride (BKC), which not only acts as a preservative, but also solubilizes the drug in its micellar structure. However, on long term use, such BKC-containing eye drops may be harmful to the eye surface. such BKC containing eyedrops are not stable at room temperatures, and may require storage at 2-8 degrees C

Our product contains BKC-free Latanosprost for improved retention in the eye. This is a non infringing formulation to the market leader Xalantan® with similar strength, dosing, etc. Removal of BKC reduces tearing, burning, itching, and hence reduces drainage from the surface of the eye. Another advantage is that our product contains latanoprost in an unbound form, which also enables its partition across eye tissues. Our product does not need any special refrigeration for storage/ transport.

SPARC has completed a Phase III clinical trial in India, where the product showed improved safety profile and eye comfort.

 
 
 
 
 
 
 
                                                                                            Technology
   
Home
About Us
NCE Projects
NDDS Projects
Timelines
Investors
Press
Contact Us
Careers
Site Map